Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials
ConclusionReduction of MVE is proportional to the magnitude of LDL-C lowering across a broad spectrum of on-treatment levels in secondary prevention. Statin intensification and add-on treatment with PCSK9 inhibitors or ezetimibe are associated with significant reduction of cardiovascular morbidity in this very high-risk population.
Source: European Heart Journal - Category: Cardiology Source Type: research
More News: Bile | Cardiology | Cardiovascular | Cholesterol | Databases & Libraries | Heart | Heart Attack | Statin Therapy | Stroke | Vytorin | Zetia